New Developments in Interventional Oncology: Liver Metastases from Colorectal Cancer

Joseph R. Kallini, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ahsun Riaz, Robert J Lewandowski, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90). The National Comprehensive Cancer Network recommends LRT for unresectable CRLM refractory to chemotherapy. The following is a review of LRT in CRLM, including salient features, advantages, limitations, current roles, and future considerations.

Original languageEnglish (US)
Pages (from-to)373-380
Number of pages8
JournalCancer Journal (United States)
Volume22
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
Therapeutics
Yttrium
Drug Therapy
Interventional Radiology
Microwaves
Cause of Death
Neoplasms

Keywords

  • Ablation
  • DEBIRI
  • colorectal liver metastases (CRLM)
  • pump FUDR
  • transarterial chemoembolization (TACE)
  • yttrium 90 (Y)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kallini, Joseph R. ; Gabr, Ahmed ; Abouchaleh, Nadine ; Ali, Rehan ; Riaz, Ahsun ; Lewandowski, Robert J ; Salem, Riad. / New Developments in Interventional Oncology : Liver Metastases from Colorectal Cancer. In: Cancer Journal (United States). 2016 ; Vol. 22, No. 6. pp. 373-380.
@article{d1ce147dcdcd4f1a91b0854e2b57f02b,
title = "New Developments in Interventional Oncology: Liver Metastases from Colorectal Cancer",
abstract = "Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial {"}bland{"} embolization, transarterial chemoembolization, and radioembolization with yttrium 90). The National Comprehensive Cancer Network recommends LRT for unresectable CRLM refractory to chemotherapy. The following is a review of LRT in CRLM, including salient features, advantages, limitations, current roles, and future considerations.",
keywords = "Ablation, DEBIRI, colorectal liver metastases (CRLM), pump FUDR, transarterial chemoembolization (TACE), yttrium 90 (Y)",
author = "Kallini, {Joseph R.} and Ahmed Gabr and Nadine Abouchaleh and Rehan Ali and Ahsun Riaz and Lewandowski, {Robert J} and Riad Salem",
year = "2016",
month = "11",
day = "1",
doi = "10.1097/PPO.0000000000000226",
language = "English (US)",
volume = "22",
pages = "373--380",
journal = "Cancer Journal",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

New Developments in Interventional Oncology : Liver Metastases from Colorectal Cancer. / Kallini, Joseph R.; Gabr, Ahmed; Abouchaleh, Nadine; Ali, Rehan; Riaz, Ahsun; Lewandowski, Robert J; Salem, Riad.

In: Cancer Journal (United States), Vol. 22, No. 6, 01.11.2016, p. 373-380.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New Developments in Interventional Oncology

T2 - Liver Metastases from Colorectal Cancer

AU - Kallini, Joseph R.

AU - Gabr, Ahmed

AU - Abouchaleh, Nadine

AU - Ali, Rehan

AU - Riaz, Ahsun

AU - Lewandowski, Robert J

AU - Salem, Riad

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90). The National Comprehensive Cancer Network recommends LRT for unresectable CRLM refractory to chemotherapy. The following is a review of LRT in CRLM, including salient features, advantages, limitations, current roles, and future considerations.

AB - Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90). The National Comprehensive Cancer Network recommends LRT for unresectable CRLM refractory to chemotherapy. The following is a review of LRT in CRLM, including salient features, advantages, limitations, current roles, and future considerations.

KW - Ablation

KW - DEBIRI

KW - colorectal liver metastases (CRLM)

KW - pump FUDR

KW - transarterial chemoembolization (TACE)

KW - yttrium 90 (Y)

UR - http://www.scopus.com/inward/record.url?scp=85002781919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002781919&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000226

DO - 10.1097/PPO.0000000000000226

M3 - Review article

C2 - 27870679

AN - SCOPUS:85002781919

VL - 22

SP - 373

EP - 380

JO - Cancer Journal

JF - Cancer Journal

SN - 0765-7846

IS - 6

ER -